Bullous and mucous membrane pemphigoid show a mixed response to rituximab: Experience in seven patients

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 10, 2011, Pages 1238-1240

  Lourari, S ^a   Herve, C ^a   Doffoel Hantz, V ^b   Meyer, N ^a   Bulai Livideanu, C ^a   Viraben, R ^a   Maza, A ^a   Adoue, D ^c   Bedane, C ^b   Paul, C ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; ETANERCEPT; IMMUNOGLOBULIN G; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; AGED; ANTIBODY DETECTION; BULLOUS PEMPHIGOID; CLINICAL ARTICLE; COMORBIDITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; INFUSION; KIDNEY DISEASE; LETTER; LUNG DISEASE; MALE; MUCOUS MEMBRANE PEMPHIGOID; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SKIN CANCER; SKIN DEFECT; TREATMENT INDICATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGOID, BULLOUS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80053045297     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03889.x     Document Type: Letter

References (11)

1. Joly P, D'Incan M, Musette P,. Rituximab for pemphigus vulgaris. N Engl J Med 2007; 356: 521-522.
2. Reguiaï Z, Tchen T, Perceau G, Bernard P,. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol 2009; 136: 431-434.
3. Saraceno R, Citarella L, Spallone G, Chimenti S,. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol 2008; 33: 154-155.
4. Schulze J, Bader P, Henke U, Rose MA, Zielen S,. Severe bullous pemphigoid in an infant: successful treatment with rituximab. Pediatr Dermatol 2008; 25: 462-465.
5. Saouli Z, Papadopoulos A, Kaiafa G, Girtovitis F, Kontoninas Z,. A new approach on bullous pemphigoid therapy. Ann Oncol 2008; 19: 825-826.
6. Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J,. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 2002; 30: 327-329.
7. Chee R, Nagendran V, Bansal A, Casie Chetty SN, Harland C,. B-cell targeted therapy alone may not be effective in bullous pemphigoid. Clin Exp Dermatol 2007; 32: 111-112.
8. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M,. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352-356.
9. Schumann T, Schmidt E, Booken N, Goerdt S, Goebeler M,. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol 2009; 89: 101-102.
10. Ross AH, Jaycock P, Cook SD, Dick AD, Tole DM,. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol 2009; 93: 421-422.
11. Taverna JA, Lerner A, Bhawan J, Demierre MF,. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol 2007; 6: 731-732.